Axsome Therapeutics Stock Surges Over 20% Following FDA Approval Expansion
Axsome Therapeutics (NASDAQ: AXSM) saw its shares rise over 20% in April after the U.S. Food and Drug Administration approved Auvelity for treating agitation associated with Alzheimer's disease, expanding beyond its original antidepressant use.
